A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Trial Profile

A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Neurofibromatoses
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 15 Dec 2017 to 2 Jul 2024.
    • 27 Jul 2017 Planned primary completion date changed from 15 Dec 2017 to 10 Sep 2019.
    • 29 Dec 2016 Early phase results (n=24) published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top